Anthera Pharmaceuticals Announces Personnel Changes

             Anthera Pharmaceuticals Announces Personnel Changes

PR Newswire

HAYWARD, Calif., June 12, 2013

HAYWARD, Calif., June 12, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice
President, Finance and Administration. In this position, Ms. Liu will oversee
the finance, investor relations and general administration functions of
Anthera in addition to her role as Principal Accounting Officer.

"Since the early days of Anthera, Ms. Liu has done an extraordinary job
heading up the finance function of Anthera including leading the company
through its Initial Public Offering and subsequent fund raising efforts. Ms.
Liu has been responsible for the company's planning, accounting and financial
reporting functions, and oversees the finance team supporting the R&D and G&A
functions. With 14 years of combined public accounting and industry
experience focusing in life science, we know Ms. Liu will continue to be the
driving force behind our finance function and look forward to her excelling in
her new role," said Paul F. Truex, President and Chief Executive Officer of

Ms. Liu has served as the Company's Vice President, Finance since January
2011. Prior to that, she served as Anthera's Corporate Controller since
October 2007. Ms. Liu joined the Company as Director of Finance in April
2007. Prior to that, Ms. Liu served as SEC Reporting and Technical Accounting
Manager at Renovis, Inc., a clinical-stage pharmaceutical company, from
October 2005 to March 2007. Ms. Liu has been a Certified Public Accountant
since 2007 and was a part of the audit and assurance practice of Ernst &
Young, LLP. from 2000 to 2005, focusing primarily in the life science
industry. Ms. Liu holds a B.S. in business administration with a
concentration in accounting from San Francisco State University.

Effective June 30^th, 2013 Anthera's Chief Business Officer and Chief
Financial Officer, Christopher Lowe will leave the company to pursue
entrepreneurial opportunities. "The Board and management of Anthera would
like to thank Chris for his years of dedicated service. Chris's financial
leadership and experience have been instrumental in providing funding for
Anthera's development programs. As a result of his efforts we are now well
positioned to accomplish our goals with blisibimod over the coming years.
Chris joined us before we became a publicly traded company and was a key part
of Anthera's Initial Public Offering, several follow on offerings, and recent
debt financings. We greatly appreciate Chris's efforts and wish him all the
best in his future endeavors," said Paul F. Truex. "The Audit Committee of our
Board of Directors will continue to provide independent financial oversight."

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its proposed offering, including its intention to offer and sell shares, its
intention to grant the underwriters an option to purchase additional shares
and its intended use of proceeds from the offering. Such statements are based
on the Company's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual results to
differ materially, including but not limited to the risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the proposed offering, as well as those set forth in the
Company's public filings with the SEC, including the Company's Annual Report
on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form
10-Q for the quarter ended March 31, 2013. The Company disclaims any intent
or obligation to update any forward-looking statements, whether because of new
information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., or

SOURCE Anthera Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.